Specific features of gastroesophageal reflux disease associated with obesity and overweight


Cite item

Full Text

Abstract

Aim. To reveal the specific features of gastroesophageal reflux disease (GERD) associated with obesity and overweight, by investigating the clinical and endoscopic manifestations of the disease, 24-hour pH-metry scores, and leptin levels. Subjects and methods. A total of 131 patients with GERD were examined. The data about complaints and those from life and medical histories were collected; anthropometric measurements and the results of blood biochemical tests, esophagoduodenoscopy (EPDS), and pH-metry were assessed; and the serum levels of leptin and its receptor were estimated. The patients were allocated into a study group (104 obese and/or overweight patients) and a comparison one (27 normal weight people). Results. Waist circumference, hip circumference, and blood glucose levels proved to be statistically significantly higher in the study group (p<0.00000, p<0.00002, and p<0.02, respectively). The obese patients were found to have a statistically significantly higher level of leptin and a lower level of its soluble receptors: the median leptin levels were 30.42 (13.42—45.62) ng/ml in the study group and 5.47 (3.35—7.68) ng/ml in the comparison group; the median levels of the receptors were 18.83 (14.98—25.11) ng/ml and 30.93 (24.68—33.53) ng/ml, respectively). This group showed a moderate negative correlation between these indicators (rs=–0.451; p<0.0004). The study group displayed higher pH values in the gastric cardia and body (p<0.05 and p<0.04, respectively). The mucosal contact time with the refluxate having with a low pH value (<4) in the above segments turned out to be longer in the comparison group (p<0.05). There were weight-independent relationships of the leptin level to its spread, aggressiveness quotient, to the highest pH value in the gastric cardia and body, and to the mucosal contact time with the refluxate having a pH below 4.0 (rs=0.543; p<0.006; rs=0.432; p<0.04; rs=0.431; p<0.04; rs=–0.450; p<0.03, respectively), leptin receptors with a pH ratio in the gastric cardia and body, to the number of reflux episodes longer than 5 minutes in the esophagus, and to the De Meester index for this indicator (rs=0.471; p<0.04; rs=–0.455; p<0.04; rs=–0,454; p<0.04, respectively). Conclusion. Obese and overweight patients develop GERD in the presence of leptin resistance and biliary tract disease, which determines the specific features of the disease (alkaline or mixed refluxate) and the need for individualized therapy.

References

  1. Obesity. World Gastroenterology Organization Global Guideline. 2009. Доступно по: http://www.worldgastroenterology.org/obesity.htmд.
  2. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R and the Global Consensus Group. Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900-1920. doi: 10.1111/j.1572-0241.2006.00630.x.
  3. Guy Boeckxstaens, Hashem B El-Serag, André JPM Smout, Peter J. Kahrilas Symptomatic reflux disease: the present, the past and the future. Postgrad Med J. 2015;91:46-54. doi: 10.1136/postgradmedj-2013-306393rep.
  4. Drahos J, Ricker W, Parsons R, Pfeiffer RM. Metabolic Syndrome Increases Risk of Barrett Esophagus in the Absence of Gastroesophageal Reflux: An Analysis of SEER-Medicare Data. J Clin Gastroenterol. 2014;49(4):285-288. doi: 10.1097/mcg.0000000000000119.
  5. Осипенко М.Ф., Бикбулатова Е.А., Жук Е.А., Скалинская М.А. Пищевод Баррета — современное состояние проблемы. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2007;17(4):11-19.
  6. Wiklund I. Review of the quality of life and burden of illness in gastroesophageal reflux disease. Digestive Diseases. 2004;22(2):108-114. doi: 10.1159/000080308.
  7. Альгинаты — новые средства на основе природных соединений в лечении гастроэзофагеальной рефлюксной болезни и других кислотозависимых заболеваний органов пищеварения. Методические рекомендации. СПб.; 2008.
  8. Боровиков В.П. STATISTICA: искусство анализа данных на компьютере. Для профессионалов. СПб.: Питер; 2001.
  9. Гланц С. Медико-биологическая статистика. Пер. с англ. С. Гланц. М.: Практика; 1998.
  10. Зайцев В.М. Прикладная медицинская статистика. В.М. Зайцев, В.Г. Лифляндский, В.И. Маринкин. СПб.: Фолиант; 2003.
  11. Hashem B El-Serag, Gulchin A Ergun, John Pandolfino. Obesity increases oesophageal acid exposure. Gut. 2007;56:749-755. doi: 10.1136/gut.2006.100263.
  12. Acosta A, Camilleri M. Gastrointestinal morbidity in obesity. Annals of the New York Academy of Sciences. 2014;1311:42-56. doi: 10.1111/nyas.12385.
  13. Ierardi E, Rosania R, Zotti M, Principe S, Laonigro G, Giorgio F, de Francesco V, Panella C. Metabolic syndrome and gastro-esophageal reflux: A link towards a growing interest in developed countries. World J Gastrointest Pathophysiol. 2010;1(3):91-96. doi: 10.4291/wjgp.v1.i3.91.
  14. Бутрова С.А. От эпидемии ожирения к эпидемии сахарного диабета. Consilium Medicum. 2003;5(9):23-28.
  15. Hajar N, Castell DO, Ghomrawi H, Rackett R, Hila A. Impedance pH confirms the relationship between GERD and BMI. Dig Dis Sci. 2012;57:1875-1879. doi: 10.1007/s10620-012-2131-6.
  16. Miwa H, Kondo T, Oshima T, Fukui H, Tomita T, Watari J. Esophageal sensation and esophageal hypersensitivity — overview from bench to bedside. J Neu-rogastroenterol Motil. 2010;16:353-362. doi: 10.5056/jnm.2010.16.4.353.
  17. Filiz Akyüz, Ahmet Uyankoglu, Fatih Ermis. Gastroesophageal reflux in asymptomatic obese subjects: An esophageal impedance-pH study. World J Gastroenterol. 2015;21(10):3030-3034. doi: 10.3748/wjg.v21.i10.3030.
  18. Miele L, Cammarota G, Vero V, Racco S. Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms. Dig Liver Dis. 2012;44(12):1032-1036. doi: 10.1016/j.dld.2012.08.005.
  19. Furukawa N, Iwakiri R, Koyama T et al. Proportion of reflux esophagitis in 6010 Japanese adults: prospective evaluation by endoscopy. J Gastroenterol Aug. 1999;34(4):441-444. Доступно по: http://link.springer.com/article/10.1007%2Fs005350050293.
  20. Paul Chang, Frank Friedenberg. Obesity & GERD. Gastroenterol Clin North Am. 2014;43(1):161-173. doi: 10.1016/j.gtc.2013.11.009.
  21. Nan Cai, Guo-Zhong Ji, Zhi-Ning Fan. Association between body mass index and erosive esophagitis: A meta-analysis. World J Gastroenterol. 2012;18(20):2545-2553. doi: 10.3748/wjg.v18.i20.2545.
  22. Ливзан М.А., Кононов А.В. Клинические и фармакоэкономические аспекты антисекреторной терапии гастроэзофагеальной рефлюксной болезни. Экспериментальная и клиническая гастроэнтерология. 2004;4:55-60.
  23. Shigemura N, Ohta R, Kusakabe Y, Miura H, Hino A, Koyano K, Nakashima K, Ninomiya Y. Leptin modulates behavioral responses to sweet substances by influencing peripheral taste structures. Endocrinology. 2004;145(2):839-847.
  24. Ливзан М.А., Лаптева И.В., Лялюкова Е.А. Гастроэзофагеальная рефлюксная болезнь: особенности течения у лиц с метаболическим синдромом. Медицинский совет. 2014;13: 10-12.
  25. Rubenstein JH, Morgenstern H, McConell D. Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett’s esophagus.. Gastroenterology. 2013;145(6): 1237-1244. doi: 10.1053/j.gastro.2013.08.052.
  26. Jose M Garcia, Andres E. Splenser, Jennifer Kramer. Circulating Inflammatory Cytokines and Adipokines are Associated With Barrett’s Esophagus: a Case-Control Study. Clin Gastroenterol Hepatol. 2014;12(2):229-238. doi: 10.1016/j.cgh.2013.07.038.
  27. Ливзан М.А., Лаптева И.В., Миллер Т.С. Роль лептина и лептинорезистентности в формировании неалкогольной жировой болезни печени у лиц с ожирением и избыточной массой тела. Экспериментальная и клиническая гастроэнтерология. 2014;8(108):27-33.
  28. Косыгина А.В., Васюкова О.В. Новое в патогенезе ожирения: адипокины — гормоны жировой ткани. Проблемы эндокринологии. 2009;55(1):44-51.
  29. Haitao Pan, Jiao Guo, Zhengquan Su. Advances in understanding the interrelations between leptin resistance and obesity. Physiology & Behavior. 2014;130:157-169. doi: 10.1016/j.physbeh.2014.04.003.
  30. Crujeiras AB, Carreira MC, Cabia B, Andrade S, Amil M, Casanueva FF. Leptin resistance in obesity: An epigenetic landscape. Life Sci. 2015;140:57-63. doi: 10.1016/j.lfs.2015.05.003.
  31. Nam SY, Choi IJ, Ryu KH, Park BJ, Kim YW, Kim HB, Kim JS. The Effect of Abdominal Visceral Fat, Circulating Inflammatory Cytokines, and Leptin Levels on Reflux Esophagitis. J Neurogastroenterol Motil. 2015;21(2):247-254. doi: 10.5056/jnm14114.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies